Tag: GlobeNewswire

Media Release

• Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials underway and study start targeted for H2 CY27.
• IMP761, the Company’s agonist anti-LAG-3 antibody for autoimmune diseases, is now a co-priority alongside efti and will be the subject of a late breaking poster at the American College of Rheumatology (ACR) Convergence in November 2026.
• The ongoing root cause analysis following the discontinuation of TACTI-004 has identified structural differences between the 2000 L scale efti used in TACTI-004 and the 200 L scale efti used in earlier successful clinical studies. A new manufacturing run of efti at 200 L scale has been contracted.
• The Company received an A$0.86 million cash rebate under the Australian Government’s R&D Tax Incentive for eligible FY2025 R&D activities and, subsequent to the end of the quarter, €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) program for eligible CY2025 R&D activities.
• Cash and term deposits of A$48.50 million at 30 September 2026, with cash runway expected to extend well into H1 CY28.

SYDNEY, AUSTRALIA, Oct. 29, 2026 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, provides an update on its activities for the quarter ended 30 September 2026 (Q1 FY27).

EFTILAGIMOD ALFA DEVELOPMENT PROGRAM FOR CANCER

TACTI-004 (KEYNOTE-F91) – Phase III Trial in 1L NSCLC

Following the early discontinuation of the TACTI-004 study, Immutep has been conducting a detailed root cause analysis.

In September, Immutep announced that the ongoing root cause analysis identified structural differences between the efti used in TACTI-004 and the efti used in earlier successful clinical studies. These differences (e.g. a subtle difference in N-glycan structure) are considered potentially relevant given the markedly different immune activation profile observed in TACTI-004 compared to previous trials and the unexpected clinical outcome of the study.

Based on the currently available data from the root cause analysis to date, Immutep believes that the unexpected outcome of TACTI-004 cannot be explained by clinical factors (e.g. suboptimal protocol, substantial imbalance between treatment arms or safety findings) or trial execution factors (e.g. invalid randomisation pattern or general clinical trial conduct).

The Company will provide a further update on the root cause analysis at its Annual General Meeting on 27 November 2026.

New Manufacturing Run

Based on the findings from the root cause analysis to date, Immutep has contracted a manufacturing run of efti at 200 L scale. Ten GMP batches of efti have previously been manufactured at 200 L scale and used in successful Phase I and Phase II clinical studies of efti, including TACTI mel, TACTI-002 and INSIGHT-003. In contrast, TACTI-004 was conducted exclusively with efti manufactured at 2,000 L scale.

Future Clinical Development Focus

Immutep currently intends to focus the potential registration-directed clinical development of efti on:

• HNSCC in patients with CPS <1; and
• the neoadjuvant setting of STS.

This focus reflects the compelling clinical data generated to date, the Company’s interactions with the FDA, regulatory designations obtained, unmet medical need and substantial market potential in these indications.

Preparations for the next phase of clinical trials have commenced. Subject to final decisions on strategy and trial design, regulatory interactions, manufacturing timelines, partnering and resources, Immutep is targeting study start during H2 CY27.

Immutep’s licensing partner, Dr. Reddy’s Laboratories (“DRL”), has been consulted on and is supportive of this approach. The Company is also in preliminary discussions with other parties regarding the proposed development pathway.

INSIGHT-003 – Phase I Trial in Non-Squamous 1L NSCLC

The investigator-initiated INSIGHT-003 Phase I trial has been completed.

In this study, the combination of efti with KEYTRUDA^® and chemotherapy has generated strong objective response rates (ORR) and disease control rates (DCR) in 51 evaluable patients with advanced or metastatic non-squamous 1L NSCLC across all PD-L1 expression levels.

As previously announced, mature overall survival (OS) results from INSIGHT-003 (data cut-off 27 March 2026) demonstrated a median overall survival (mOS) of 30.9 months in the overall study population.¹

These results compare favourably with historical benchmarks. No new safety signal was identified since the previous data cut-off.

EFTISARC-NEO – Phase II Trial in Soft Tissue Sarcoma

Immutep announced in September that one of the two indications in which it intends to focus the registration-directed clinical development of efti is the neoadjuvant setting of soft tissue sarcoma (STS).

The investigator-initiated EFTISARC-NEO Phase II trial evaluating efti in combination with radiotherapy and KEYTRUDA^® in the neoadjuvant setting for resectable STS has met its primary endpoint, with a median 51.5% tumour hyalinization/fibrosis in the evaluable population (N=38), significantly exceeding the prespecified 35% target (p<0.001). Patients also showed strong immune system activation in line with efti’s mode of action, including statistically significant increases in the expression of key cytokines and chemokines in peripheral blood. Patients are continuing to be followed up for disease-free survival.

Immutep also received Orphan Drug Designation for efti in this setting from the FDA in April 2026.

Subsequent to the end of the quarter, on 23 October 2026, Immutep announced health-related quality of life (HRQoL) data from the EFTISARC-NEO trial, presented in an ePoster at the ESMO Congress 2026 in Madrid. HRQoL, a secondary endpoint, remained stable during neoadjuvant treatment, with no statistically significant deterioration in any measured scale. After surgery, patients reported statistically significant improvements in the QLQ-C30 summary score (6.0 points; p=0.008) and in role and social functioning, and reported significantly lower fatigue than at baseline (by up to 14.2 points; p=0.001).

AIPAC-003 – Phase II Trial in Metastatic Breast Cancer

The AIPAC-003 Phase II trial evaluated efti in combination with chemotherapy in hormone receptor positive (HR+), HER2 negative/low metastatic breast cancer that is resistant to endocrine-based therapy, as well as in metastatic triple-negative breast cancer not eligible for PD-(L)1-based therapy. As previously announced, the trial closed effective 30 June 2026.

Investigator-Initiated Phase II Trial for Neoadjuvant Efti in HR+/HER2-Negative Breast Cancer

As previously announced, a proposed investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in early-stage HR+/HER2-negative breast cancer remains on hold pending completion of the root cause analysis related to TACTI-004 and further strategic decisions.

IMP761 DEVELOPMENT PROGRAM FOR AUTOIMMUNE DISEASE

IMP761 – Phase I Trial

Development of IMP761, the Company’s agonist anti-LAG-3 antibody for autoimmune diseases, continues in line with previously disclosed plans and is now a co-priority alongside efti.

In June 2026, Immutep presented positive interim data from its placebo-controlled, double-blind, randomized, first-in-human Phase I study evaluating IMP761, a first-in-class LAG-3 agonist antibody, at the EULAR 2026 Congress in London.

The single ascending dose part of the study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers, with IMP761 well tolerated across all dose levels tested.

The data also showed statistically significant pharmacodynamic activity, including reduced local inflammatory responses and attenuated T-cell activity compared to placebo, with the 7 mg/kg dose achieving a statistically significant inhibition in skin blood perfusion (p = 0.029).

The pharmacokinetic profile supports once-every-four-weeks dosing. These encouraging results support further clinical evaluation of IMP761 in autoimmune diseases driven by T-cell-mediated inflammation, such as rheumatoid arthritis or type 1 diabetes, with additional trial updates expected at the American College of Rheumatology (ACR) Convergence 2026, taking place from 6 to 11 November 2026 in Orlando, Florida, USA. As announced on 19 October 2026, a late-breaking abstract on IMP761 has been accepted for poster presentation at the conference on 10 November 2026.

INTELLECTUAL PROPERTY

During the quarter, Immutep continued to build its patent estate and was granted three new patents.

In particular, as announced in July, Immutep was granted its fourth United States patent directed to efti in combination with a PD-1 pathway inhibitor.

The Company was also granted a Russian patent directed to IMP761 and an Australian patent directed to an assay used to measure the potency of IMP761 as part of a quality control step in the production of the agonist LAG-3 antibody.

CORPORATE AND FINANCIAL SUMMARY

Change to American Depositary Share Ratio

Following the Nasdaq minimum bid price deficiency notification announced on 30 April 2026, Immutep announced on 21 September 2026 a change to the ratio of its American Depositary Shares (ADSs), effective 28 September 2026 (US Eastern time), from one ADS representing 10 ordinary shares to one ADS representing 200 ordinary shares.

For holders of ADSs, the change has the same practical effect as a reverse split of the ADSs on the basis of one new ADS for every 20 ADSs held. The Company’s ordinary shares quoted on the ASX are not affected, the number of ordinary shares on issue does not change, and the change does not alter the proportionate economic interest of any shareholder or ADS holder in the Company.

Subsequent to the end of the quarter, on 13 October 2026 Immutep announced that it had received written notification from Nasdaq confirming that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), following a closing bid price at or above US$1.00 per ADS for 10 consecutive business days from 28 September 2026 to 9 October 2026. Nasdaq has advised that the matter is now closed.

Board and Audit and Risk Committee

Subsequent to the end of the quarter, Pete Meyers resigned as a Non-Executive Director effective 2 October 2026. As announced on 9 October 2026, following Mr Meyers’ resignation the Audit and Risk Committee comprises two members and the Company is not currently in compliance with ASX Listing Rule 12.7. The Board has commenced a search for an additional independent non-executive director with financial and accounting expertise who, once appointed, is intended to join the Audit and Risk Committee and be invited to chair it. The Company expects to complete the appointment during the financial year ending 30 June 2027. In the interim, Lis Boyce is acting as Chair of the Audit and Risk Committee. The Committee’s recommendations on financial reporting, accounting judgements and external audit continue to be referred to the full Board.

Cash Flow Summary

During the quarter, Immutep continued to exercise prudent cash management, particularly in light of the TACTI-004 Phase III discontinuation.

In September, Immutep announced it had received an A$0.86 million cash rebate under the Australian Government’s R&D Tax Incentive for eligible R&D activities conducted in FY2025. Following AusIndustry’s approval of an Advance Overseas Finding, certain of Immutep’s overseas R&D activities were eligible alongside its Australian activities.

Subsequent to the end of the quarter, on 28 October 2026, Immutep announced it had received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) research tax incentive program for eligible R&D activities conducted in calendar year 2025. Immutep is eligible for the CIR through its French subsidiary, Immutep S.A.S., which conducts research at its laboratory in France. As this payment was received after 30 September 2026, it is not included in the quarter-end cash and term deposits balance.

The non-dilutive funding from both incentives will be applied to Immutep’s current R&D activities for its product candidates, efti and IMP761. Immutep’s expected cash reach extends well into the first half of CY28.

The net cash used in G&A activities in the quarter was A$1.2 million compared to A$1.5 million in Q4 FY26.

In Q1 FY27, cash receipts from customers were A$6K, which is mainly due to research material sales. Net cash used in R&D activities was A$16.5 million for the quarter, compared with A$22.0 million in Q4 FY26, with the decrease primarily reflecting a decrease in clinical trial activity as the Company continued the close-out relating to TACTI-004. As invoices are generally payable approximately one month after issue, TACTI-004 payments are expected to decline significantly in subsequent quarters.

Payment for staff costs was A$2.4 million in the quarter, compared to A$2.5 million in Q4 FY26. Total net cash outflows used in operating activities in the quarter were A$19.1 million compared to net cash outflows of A$38.9 million in Q4 FY26.

Total net cash inflow received in investing activities for the quarter was A$5.0 million, which is mainly due to the transfer back of matured short-term investments to cash at bank. The short-term investments are comprised of term deposits with maturities of greater than 3 months and less than 12 months.

As at 30 September 2026, Immutep had total cash and term deposits of approximately A$48.50 million, comprising cash and cash equivalents of A$48.41 million and term deposits of A$0.09 million.

Payments to related parties and their associates of A$456K, comprises non-executive directors’ fees and executive directors’ remuneration.

After the TACTI-004 Phase III futility outcome, the Company has initiated cost reduction measures to preserve capital and extend its cash runway. These measures include a targeted reduction in headcount and other operating expense reductions, most of which took effect from the start of FY27. The discontinuation of TACTI-004 also precipitates a reduction in cash outlays due to the trial activity being wound down. At the time of preparing this report, the Company expects its cash runway to extend well into H1 of CY28.

About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to the Lymphocyte Activation Gene-3 (LAG-3)/MHC Class II immune control mechanism, and its diversified product portfolio harnesses the ability of this mechanism to stimulate or suppress the immune system. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward Looking Statements
This announcement contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995, including statements regarding the ongoing root cause analysis relating to TACTI-004; the manufacture of efti at 200 L scale; Immutep’s intended clinical development focus for efti in HNSCC and STS, including the design, regulatory interactions and targeted start of future clinical trials; partnering discussions, including with DRL and other parties; the anticipated timing of further clinical updates for IMP761; expected reductions in TACTI-004 payments and other operating costs; and Immutep’s expected cash runway. Forward-looking statements can be identified by words such as “anticipate”, “believe”, “expect”, “intend”, “plan”, “target”, “potential”, “may”, “will”, “should” and similar expressions.

Forward-looking statements are based on Immutep’s current expectations and assumptions as at the date of this announcement and are subject to known and unknown risks, uncertainties and other factors, many of which are beyond Immutep’s control, that could cause actual results to differ materially from those expressed or implied. These include: the findings and timing of the root cause analysis, which is not complete and may not identify a conclusive cause for the outcome of TACTI-004; whether efti manufactured at 200 L scale will be comparable to efti used in earlier clinical studies, and the timing and success of the new manufacturing run; the results of ongoing and future clinical trials, which may not replicate earlier results; the requirements of the FDA and other regulators for future trials; Immutep’s ability to enter into partnering arrangements and the terms of any such arrangements; the actual timing and amount of TACTI-004 wind-down costs and other expenditure; the timing and amount of R&D tax incentives; Immutep’s ability to obtain additional funding; and the other risks described in Immutep’s filings with the ASX and the US Securities and Exchange Commission, including its most recent Annual Report on Form 20-F.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Except as required by law or the ASX Listing Rules, Immutep undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

1. Immutep press release – 13 July 2026

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

U.S. Investors/Media:
Matthew Beck
Ph: +1 (917) 415-1750; matthew.beck@astrpartners.com

On-site mill services agreement continues long-standing relationship dating back to 1999

LONDON, Oct. 29, 2026 (GLOBE NEWSWIRE) — Harsco Environmental, a division of Enviri Corporation (NYSE: NVRI) and a global leader in providing innovative environmental solutions, today announced it has signed a 10-year contract renewal with EZS, a steel mill in Sadat City, Egypt, with a production capacity of one million tons of rebar per year.

Under the agreement, Harsco Environmental will provide furnace and scrap management services at the EZS site, which includes steel-making facilities such as an electric arc furnace, a billet caster, and two rolling mills. Harsco Environmental will help EZS maximize operational efficiency, recover valuable materials, and improve environmental performance.

“The renewal of this long-standing partnership demonstrates the strength of our collaboration with EZS and the value Harsco Environmental delivers to steel producers through safe, efficient, and sustainable mill services,” said Harsco Environmental’s Regional President of EMEA, Stéphane Boissinot. “This contract renewal both reinforces our regional presence and creates opportunities to drive future growth.”

EZS is owned by EZZ Steel, the leading steel producer in the Middle East and North Africa, with an average annual production of around 6.5 million tons. This is one of three contracts Harsco Environmental has with EZZ Steel. The Company also provides services to EZDK in Alexandria and to EFS in Sokhna, further supporting steelmaking operations across Egypt.

For more information about Harsco Environmental and its solutions, visit https://www.harsco-environmental.com.

About Harsco Environmental

Enviri’s Harsco Environmental division is the largest and most comprehensive provider of onsite material processing and environmental services to the global metals industry, with operations at over 130 customer sites across more than 32 countries. Harsco Environmental is a technology partner delivering cleaner, more efficient metal production, providing customers with economically and environmentally viable solutions for the treatment and reuse of production co-products. Visit harsco-environmental.com to learn more.

Investor Contact	Media Contact
David Martin	Karen Tognarelli
+1.267.946.1407	+1.717.480.6145
dmartin@enviri.com	ktognarelli@enviri.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a712ede4-b17f-4840-be2c-c539f2b4b057

$100 from every bottle sold will benefit Denver men’s ice hockey scholarships

DENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) — Breckenridge Distillery, an award-winning craft distillery and subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), and University of Denver Athletics today announced the release of a limited-edition Breckenridge Single Barrel Bourbon Whiskey celebrating the Denver Pioneers’ 2026 NCAA Men’s Ice Hockey National Championship.

The commemorative release celebrates Denver’s record 11th national championship while supporting the future of the program, with $100 from every bottle sold benefiting the Denver Men’s Ice Hockey Scholarship. The 230-bottle release was created from a special single barrel selected in collaboration with Denver Athletics supporters at Breckenridge Distillery and is bottled at 101.7 proof.

“Denver hockey’s tradition of excellence reflects the same values we bring to every bottle we make: dedication, craftsmanship and pride in representing Colorado at the highest level,” said Bryan Nolt, Founder and CEO of Breckenridge Distillery. “Having DU Athletics supporters join us in the barrel room to help select this whiskey made the process truly collaborative, and knowing the proceeds will support the next generation of Denver hockey players makes this release even more meaningful.”

The Pioneers captured their record 11th national championship on April 11, 2026, defeating Wisconsin in Las Vegas. Denver holds the all-time record with 11 national championships, including four in the past decade in 2017, 2022, 2024 and 2026. Under Richard and Kitzia Goodman Head Hockey Coach David Carle, Denver has captured its three most recent titles, delivering three championships in five years.

“Last spring’s 11th Denver hockey national championship, the program’s third title in five years, was a special moment in Denver Athletics history,” Vice Chancellor for Athletics and Ritchie Center Operations Josh Berlo said. “Special moments, especially ones of this magnitude, call for special commemoration. We are excited that a close group of supporters had the opportunity to provide input with Breckenridge Distillery and be a part of barrel tasting for this new product for our fans. To have a significant portion of the proceeds go towards hockey scholarships makes this a full circle commemoration and empowering future national success for the legacy and tradition that is Denver hockey.”

The collaboration brought a group of Denver Athletics supporters to Breckenridge Distillery for a behind-the-scenes experience in the barrel room. Participants toured the distillery, learned about the whiskey-making process and evaluated different barrels alongside the Breckenridge Distillery team before helping select the single barrel used for the commemorative release.

“We were welcomed with open arms at the Breckenridge distillery. They took us to a tasting area and provided us with the tools to evaluate different barrels and interact with each other and the staff,” said Tim Thompson, a University of Denver alumnus and DU Athletics supporter. “It was great fun to play a small role in this partnership between DU Athletics and Breckenridge Distillery.”

The limited-edition whiskey showcases Breckenridge Distillery’s grain-to-glass craftsmanship under the direction of Master Distiller Hans Stafsholt. Bottled at 101.7 proof, the single-barrel release offers aromas of balanced oak spice, caramel and brown sugar, followed by a creamy, viscous palate with notes of caramel, brown sugar and cinnamon and a hint of black pepper spice.

The 230-bottle limited release is available for $179.99 at Bonnie Brae Liquor, 785 S. University Blvd., Denver, Colorado, and Mondo Vino, 3601 W. 32nd Ave., Denver, Colorado. The bottle is also available for home delivery where permitted.

Age 21+. Always enjoy responsibly.

About Breckenridge Distillery
Founded in Colorado in 2008, Breckenridge Distillery is the “World’s Highest Distillery,” and is best known for its award-winning blended bourbon whiskey, a high-rye mash American-style whiskey. One of the most highly awarded distilleries in the U.S., the Breckenridge Distillery is proudly a 3x Icons of Whisky and 10x winner of Best American Blended at the World Whiskies Awards by Whisky Magazine and a 6x winner of Colorado Distillery of the Year by the New York International Spirits Competition. Most recently, Breckenridge Port Cask Finish was named World’s Best Finished Bourbon at the 2024 World Whiskies Awards, joining Breckenridge High Proof, named World’s Best Blended Whiskey, and Breckenridge Gin, named World’s Best Compound Gin at the World Gin Awards by Gin Magazine. Breckenridge spirits have been awarded 7 Double Golds at the San Francisco World Spirits Competition.

The Breckenridge Distillery is more than award-winning spirits, offering an immersive guest experience. Named one of the country’s Top Visitor Attractions by Whisky Magazine, guests can dine at the award-winning restaurant, enjoy show-stopping cocktails, explore an in-depth tasting, and get an inside look at the active production facility—including the opportunity to blend their own whiskey.

Breckenridge Distillery is a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life.

To learn more about Breckenridge Distillery, visit www.breckenridgedistillery.com. Keep up with Breckenridge Distillery on Instagram by following @breckdistillery and become a fan at facebook.com/BreckDistillery. For more information about Tilray Brands, visit www.tilray.com and follow @tilray on Instagram, Twitter, Facebook, and LinkedIn.

About Tilray Brands 
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages. 

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. 

Forward-Looking Statements
 Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information, please contact
Media: Breckenridge@klgpr.com, 970-771-3662
Tilray Brands Media: news@tilray.com
Investors: investors@tilray.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/133f4f69-7534-4939-8016-37e62e96f13a

JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston.

One-on-One Meetings
Dates: November 9-10, 2026

Fireside Chat
Date: Monday, November 9, 2026
Time: 2:30 p.m.-3:00 p.m. ET

A live webcast of the Guggenheim fireside chat will be available here. A replay of the webcast will be available on our website for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit www.scynexis.com.

CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com

GREENWICH, Conn., Oct. 29, 2026 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (NasdaqGS: OXLCG) (NasdaqGS: OXLCM) announced today that it will hold a conference call to discuss its second fiscal quarter earnings on Thursday, November 5, 2026 at 9:00 AM ET. The toll-free dial-in number is 1-800-715-9871, access code number 3024474. There will be a recorded replay of the call available for 30 days after the call. If you are interested in hearing the recording, please dial 1-800-770-2030. The replay pass-code number is 3024474.

About Oxford Lane Capital Corp.

Oxford Lane Capital Corp. is a publicly-traded registered closed-end management investment company principally investing in debt and equity tranches of collateralized loan obligation (“CLO”) vehicles. CLO investments may also include warehouse facilities, which are financing structures intended to aggregate loans that may be used to form the basis of a CLO vehicle.

Contact:
Bruce Rubin
203-983-5280

EL MONTE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that it will report financial results for the 2026 third quarter ended September 30, 2026 before the market opens on Thursday, November 5, 2026. The Company will host a conference call to discuss its financial results on the same day at 8:00 AM Eastern Time.

To access the conference call, participants should pre-register here to receive the dial-in information and a unique PIN. All participants are encouraged to dial-in 15 minutes prior to the conference call’s start time.

A live and archived webcast of the conference call will be accessible on the Company’s investor relations website at https://investors.gigacloudtech.com/news-events/events.

About GigaCloud Technology Inc
GigaCloud Technology Inc is a pioneer of global end-to-end B2B technology solutions for large parcel merchandise. The Company’s B2B ecommerce platform, which it refers to as the “GigaCloud Marketplace,” integrates everything from discovery and payments to logistics tools into one easy-to-use platform. The Company’s global marketplace seamlessly connects manufacturers, primarily in Asia, with resellers, primarily in the U.S., Asia and Europe, to execute cross-border transactions with confidence, speed and efficiency. The Company offers a truly comprehensive solution that transports products from the manufacturer’s warehouse to the end customer’s doorstep, all at one fixed price. The Company first launched its marketplace in January 2019 by focusing on the global furniture market and has since expanded into additional categories such as home appliances and fitness equipment. For more information, please visit the Company’s website: https://investors.gigacloudtech.com/

For investor and media inquiries, please contact:

GigaCloud Technology Inc.
ir@gigacloudtech.com
Pondel Wilkinson Inc.
Laurie Berman (Investors)	Todd Kehrli (Investors)
Lberman@pondel.com	Tkehrli@pondel.com
George Medici (Media)
gmedici@pondel.com

• BlackLine partners with S3NS to expand its services on a trusted cloud in France, addressing stringent data residency and regulatory requirements.
• Thales becomes the first customer to deploy BlackLine’s platform on S3NS’s PREMI3NS trusted cloud.
• The partnership expands BlackLine’s secure infrastructure options, enabling regulated organizations to adopt AI-powered financial operations with greater data control.

PARIS and LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) — BlackLine, Inc. (Nasdaq: BL), the Agentic Financial Operations Platform™ for the Office of the CFO, and S3NS, a joint venture controlled by Thales in partnership with Google Cloud, today jointly announced their partnership in France for a new offering hosted on a trusted cloud infrastructure, further expanding BlackLine’s European cloud footprint. This strategic alliance enables organizations with stringent data residency and sovereignty requirements to modernize financial operations while maintaining greater control over where and how their data is managed.

Thales, a global leader in Defense, Aerospace, Cyber, and Digital, will be the first customer to implement BlackLine’s platform on this new infrastructure. The platform will run on PREMI3NS, the trusted cloud offering from S3NS. To support the rollout, Thales’ digital services division will build and operate the local deployment, highlighting the company’s dual role as both a flagship customer and a key integration partner.

This investment expands BlackLine’s ability to serve organizations operating in highly regulated European environments, where data control, security and regulatory requirements are increasingly important considerations in cloud and AI adoption. “Finance cannot compromise on trust. As AI takes on more consequential work, organizations need confidence not only in the accuracy, transparency, and governance of the technology, but also in where their most sensitive financial data resides and how it is controlled,” said Philippe Omer Decugis, Senior Vice President and General Manager for EMEA at BlackLine. “Consequently, data control and regulatory compliance are becoming an increasingly important part of the AI conversation. With this investment, we are giving organizations a path to put trusted AI to work in financial operations while meeting the stringent sovereignty requirements businesses demand.”

BlackLine’s Agentic Financial Operations Platform™, powered by Studio360 and Verity™ AI, enables finance and accounting teams to unify data, automate complex processes, and orchestrate workflows, across mission-critical financial operations. Its AI agents execute specialized financial tasks, from preparing account reconciliations to matching transactions, while keeping finance leaders firmly in control. The trusted cloud deployment model brings these capabilities to organizations requiring greater control over the location and operation of their financial data.

“Our mission at S3NS is to enable organizations to modernize with leading cloud technologies while meeting the highest requirements for data control and regulatory compliance,” said Cyprien Falque, CEO of S3NS. “By providing the Trusted cloud foundation for BlackLine, we are creating an environment where organizations can adopt advanced financial technology while maintaining the control and protections their most sensitive workloads require.”

“Data sovereignty isn’t optional for an organization like Thales, it’s foundational. Being the first to implement BlackLine’s trusted cloud offering reflects our commitment to bringing advanced AI-driven finance capabilities into our operations without compromising on the security and control our business demands,” said Stéphanie Pétris, VP Group Finance Transformation at Thales.

This new French offering with S3NS builds on BlackLine’s broader investment in security, governance and trusted AI, including its ISO/IEC 42001:2023 certification for its Artificial Intelligence Management System. It is also part of BlackLine’s continued expansion of its global cloud footprint and trusted infrastructure, supporting customers as they scale digital finance and AI across increasingly complex environments.

About BlackLine
BlackLine (Nasdaq: BL) is the trust infrastructure for the AI era of finance: a future where finance drives the agentic era with intelligence, integrity, and trust rising together. The BlackLine Agentic Financial Operations Platform™, powered by Studio360 and Verity™ AI, is where the Office of the CFO scales AI across Record-to-Report, Invoice- to-Cash, and the processes where finance owns the controls and demands integrity at every step. By unifying data, embedding AI, and engineering trust into every action, BlackLine moves finance and accounting beyond reporting on the business to orchestrating it in real time. Supported by industry-leading R&D investment and world-class security practices, nearly 4,300 customers across multiple industries partner with BlackLine to lead their organizations into the future. For more information, visit blackline.com.

About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defense, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion. The Group allocates €4.5 billion per year to Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies. Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion.

About S3NS
An alliance between Thales, a global leader in data protection and cybersecurity, and Google Cloud, one of the world’s leading cloud technology providers, S3NS offers public institutions and private companies—seeking to further protect their most sensitive data—highly secure public cloud solutions to support their transition to a trusted cloud, in compliance with the SecNumCloud framework defined by ANSSI, the French National Agency for the Security of Information Systems. S3NS is a company incorporated under French law and wholly controlled by Thales.

Media Contact
Marion Bonnet, Thales and S3NS Media Relations Manager
Marion.bonnet@thalesgroup.com
+33 6 60 38 48 92

Media Contact
David Brightman, VP Brand & Corporate, BlackLine
Media.Relations@BlackLine.com

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — Magnite (Nasdaq: MGNI), the largest independent sell-side advertising company, today announced that members of its executive team will participate in the following financial conferences:

• Seaport 4th Annual TMT Conference on Tuesday, November 17th – company management will participate virtually
• RBC Global Technology, Internet, Media and Telecommunications Conference in New York City on Wednesday, November 18 – company management will participate in a fireside chat at 10:40 a.m ET
• Stephens Investment Conference in Nashville on Thursday, November 19
• Raymond James TMT and Consumer Conference in New York City on Tuesday, December 8
• Wells Fargo 10th Annual TMT Summit in Rancho Palos Verdes on Wednesday, December 9 – company management will participate in a fireside chat at 1:30 p.m. PT
• Susquehanna Technology Select Spotlight Series on Monday, December 14 – company management will participate virtually
• Needham 29th Annual Growth Conference in New York City on Wednesday, January 13 – company management will participate in a fireside chat with timing to be announced

Live webcasts of the RBC, Wells Fargo and Needham fireside chats will be available in the “Events & Presentations” section of Magnite’s investor relations website at: https://investor.magnite.com. The webcast replays will be available following the conclusion of the live presentations for 90 days.

About Magnite

We’re Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising company. Publishers use our technology to monetize their content across all screens and formats including CTV, online video, display, and audio. The world’s leading agencies and brands trust our platform to access brand-safe, high-quality ad inventory and execute billions of advertising transactions each month. Anchored in bustling New York City, sunny Los Angeles, mile high Denver, historic London, colorful Singapore and down under in Sydney, Magnite has offices across North America, EMEA, LATAM, and APAC.

Investor Relations Contact
Nick Kormeluk, 949-500-0003
nkormeluk@magnite.com

MediWound to Report Third Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Thursday, November 12^th at 8:30 a.m. Eastern Time

YAVNE, Israel, October 29, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2026, on Thursday, November 12, 2026.

Following the release, Mediwound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Conference Call & Webcast Details
Toll-Free:                1-844-676-8833
Israel:                     03-374-1008
International:          1-412-634-6869
Webcast:                Click HERE

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.  An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage development candidate, EscharEx^®, is an investigational therapy for the debridement of chronic wounds, with the potential to become a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).

MediWound Contacts:                                                        

Hani Luxenburg                                                 Daniel Ferry
Chief Financial Officer                                       Managing Director
MediWound Ltd.                                                LifeSci Advisors, LLC
ir@mediwound.com                                          daniel@lifesciadvisors.com        

First Cash Milestone Payment Under 60-Month Enterprise Order Supports Procurement and Build-Out of Dedicated AI Computing Capacity

NEW YORK, NY, Oct. 29, 2026 (GLOBE NEWSWIRE) — Quanome Technologies, Inc. (Nasdaq: QNME) (“Quanome” or the “Company”) today announced that XDT Infrastructure I, LLC (“XDT”), an indirect wholly-owned subsidiary of Quanome, has received its first milestone payment in the amount of US$13.5 million from an enterprise customer. The payment is the first customer payment toward the prepayment disclosed in Quanome’s Current Report on Form 8-K filed on October 5, 2026.

Under the customer agreement, the prepayment is payable in tranches tied to procurement milestones for the servers underlying the customer’s dedicated capacity. XDT intends to apply the prepayment substantially toward the procurement of the servers and the related build-out of the dedicated capacity.

“Receipt of this first customer payment is an important commercial milestone for Quanome and our subsidiary team at XDT,” said Yang Li, CEO of Quanome Technologies. “In a matter of weeks, we have progressed from committing to our initial infrastructure, securing a long-term enterprise order, and receiving customer funding that supports the build-out of dedicated capacity. Our focus now is delivery, deploying the infrastructure, satisfying the remaining conditions and preparing to begin service for our new customer.”

Quanome focuses on opportunities across four strategic pillars: Quantum and AI Systems; Quantum Life Sciences – Molecular Discovery; Advanced Nuclear; and Quantum-Safe Cybersecurity. XDT is the Company’s commercial AI infrastructure initiative within the Quantum and AI Systems pillar. Through XDT, Quanome is developing a managed AI computing business that gives enterprise customers access to dedicated computing capacity to run trained AI models and process new information and generate outputs, all without having to build and operate the underlying infrastructure themselves.

Quanome’s receipt of the US$13.5 million payment marks the next step in XDT’s commercial development. Quanome first announced an approximately US$18.8 million purchase agreement for 32 GPU server units in September 2026. It subsequently entered into a second purchase agreement for an additional 32 GPU server units at an aggregate price of approximately US$18.8 million and announced XDT’s first enterprise customer agreement.

XDT’s initial order with the customer has a 60-month commitment term commencing on the service-ready date and a total commitment value exceeding US$100 million, payable as a fixed monthly commitment fee. The monthly commitment is not reduced for usage below committed levels. Service commencement remains subject to the applicable service-start conditions.

The GPU server units under both purchase agreements are expected to be delivered to a designated data center in the United States, subject to the applicable commercial, supply-chain and operational conditions.

Ends. 

Media / Investor Relations Contact

www.quanometech.com

investor@quanometech.com

NOTES TO EDITORS

About Quanome Technologies

Quanome Technologies, Inc. (Nasdaq: QNME) focuses on opportunities across four strategic pillars: Quantum and AI Systems; Quantum Life Sciences – Molecular Discovery; Advanced Nuclear; and Quantum-Safe Cybersecurity. The Company combines commercial initiatives with the development of a global scientific network through its Global Quantum Council and Scientific Advisory Network. XDT is Quanome’s commercial AI infrastructure initiative within the Quantum and AI Systems pillar. Through XDT, Quanome is developing a managed AI computing business designed to give enterprise customers access to dedicated computing capacity for running AI applications.

Forward-Looking Statements

This release contains forward-looking statements, including statements regarding the application and use of customer prepayments; the purchase, delivery and deployment of GPU server units; the satisfaction of procurement and service-start conditions; the anticipated commencement of services under XDT’s customer agreement; the expected term, fees and commercial benefits of the initial order; the development and expansion of XDT; and anticipated customer and revenue opportunities. These statements are based on current plans, assumptions and expectations and involve risks and uncertainties. Actual results and timing may differ materially due to, among other things, the satisfaction of contractual conditions, customer requirements, availability and deployment of computing infrastructure, supplier and data-center performance, technical and operational matters, third-party performance, financing availability, regulatory and export-control requirements, and the accounting treatment of customer payments and service revenue. There can be no assurance that GPU server units will be delivered on the expected schedule, that services will commence on the expected timetable, that additional prepayments will be received, that the order will generate the anticipated value, or that XDT will achieve its intended commercial objectives. Additional risks are described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by applicable law.